icon-    folder.gif   Conference Reports for NATAP  
  19th Conference on Retroviruses and
Opportunistic Infections
Seattle, WA March 5 - 8, 2012
Back grey_arrow_rt.gif
Assessment of HIV Antiretroviral Drug Interactions With the HCV NS5A Replication Complex Inhibitor Daclatasvir Demonstrates a PK Profile Which Supports Coadministration With Tenofovir, Efavirenz and Atazanavir/r
  Reported by Jules Levin
19th CROI Seattle March 8 2012
Bifano M,1 Hwang C,1 Oosterhuis B,2 Hartstra J,2 Tiessen RG,2 Velinova-Donga M,2 Kandoussi H,1 Sevinsky H,1 Bertz R1
1Bristol-Myers Squibb, Research and Development, Hopewell, NJ; 2PRA EDS, Zuidlaren, The Netherlands
Bristol-Myers Squibb Posts Data Update on Daclatasvir, an NS5A Inhibitor in Phase III
Development for the Treatment of Hepatitis C

(PRINCETON, N.J., March 8, 2012) - Bristol-Myers Squibb
today posted an overview of new data on daclatasvir (or BMS-790052), we issued an Investigational Compound News (ICN) update on our website for daclatasvir (BMS-790052).
Daclatasvir is an NS5A replication complex inhibitor in Phase III development for the treatment
of hepatitis C. These data were presented Thursday, March 8, at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.